What To Know
- , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Sinai Health System in Chicago has entered into an agreement to lease and utilize a Senhance® Surgical System, which would be the first facility in Chicago to move in this direction.
- “As a health system, we seek to offer the best possible care utilizing the latest technology to all the patients we serve in our community, and we are proud to be the first hospital in Chicago to launch the Senhance surgical program,“ said Dr.
TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Sinai Health System in Chicago has entered into an agreement to lease and utilize a Senhance® Surgical System, which would be the first facility in Chicago to move in this direction.
“Our team is excited that Sinai Health System has chosen to add the Senhance Digital Laparoscopy Platform to its minimally invasive surgery program,” said Anthony Fernando, president, and chief executive officer at TransEnterix. “In the midst of the challenging times posed by COVID-19, hospitals are looking to the future and continue to seek more advanced and cost-effective technologies to treat their patients undergoing surgery. We are thrilled to partner with the excellent surgical team at Sinai Health System.”
The Senhance System is the first new abdominal robotic surgery platform to receive FDA clearance since 2000. It is the first and only digital laparoscopic surgical platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including, 3 mm micro laparoscopic instruments, eye sensing camera control and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy. In March 2020, TransEnterix received FDA clearance for the first machine vision system in robotic surgery which powers the new Intelligent Surgical Unit capability of Senhance.
“We chose the Senhance Surgical System because it offers unique capabilities in adding robotics to our surgical program,” said Dr. Carlos Sandoval-Herrera FACOG, Director of Gynecology and Chief of the Division of Minimally Invasive Gynecologic Surgery at Sinai Health System. “This technology offers the opportunity to use instruments as small as 3mm with robotic assistance, which can help offer many patients virtually scarless surgery. The advances being made with augmented intelligence utilizing this system are truly the future in using digital information to better guide and control surgery.”
“As a health system, we seek to offer the best possible care utilizing the latest technology to all the patients we serve in our community, and we are proud to be the first hospital in Chicago to launch the Senhance surgical program,“ said Dr. Airica Steed, System Chief Operating Officer and Executive Vice President of Sinai Health System. “We are pleased to build upon our excellent outcomes at the Center of Excellence in Minimally Invasive Gynecological Surgery at Sinai Health System and utilize robotic surgery with Senhance to offer patients fast recovery with minimal pain and scarring.”